Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study to Determine the Pathological Complete Response Rate and Immunomodulatory Effects of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer

NCT02685306 is registered in ClinicalTrials.gov with Peregrine Pharmaceuticals as lead sponsor.

NCT NCT02685306
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02685306 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study to Determine the Pathological Complete Response Rate and Immunomodulatory Effects of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer
Lead sponsor
Peregrine Pharmaceuticals
Phase
Phase 2
Overall status
Withdrawn
Start date
March 31, 2016
Completion date
September 30, 2017
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, er-negative pr-negative her2-negative breast cancer, er-negative pr-negative her2-negative breast neoplasms, triple negative breast cancer, triple negative breast neoplasms, triple-negative breast cancer, triple-negative breast neoplasm